Managing thrombosis and cardiovascular complications of COVID-19: answering the questions in COVID-19-associated coagulopathy

References

• Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020;127:104362.
   PubMed Web of Science ®Google Scholar
• Iba T, Levy JH, Levi M, et al. Coagulopathy in COVID-19. J Thromb Haemost. 2020 Jun;18(9):2103–2109.
   Web of Science ®Google Scholar
• Piazza G, Campia U, Hurwitz S, et al. Registry of arterial and venous thromboembolic complications in patients with COVID-19. J Am Coll Cardiol. 2020;76(18):2060–2072.
   PubMed Web of Science ®Google Scholar
• Jin S, Jin Y, Xu B, et al. Prevalence and impact of coagulation dysfunction in COVID-19 in China: a meta-analysis. Thromb Haemost. 2020;120(11):1524–1535.
   PubMed Web of Science ®Google Scholar
• Iba T, Levy JH, Connors JM, et al. The unique characteristics of COVID-19 coagulopathy. Crit Care. 2020;24(1):360.
   PubMed Web of Science ®Google Scholar
• Schnittler HJ, Feldmann H. Viral hemorrhagic fever–a vascular disease?. Thromb Haemost. 2003;89(6):967–972.
   PubMed Web of Science ®Google Scholar
• Paessler S, Walker DH. Pathogenesis of the viral hemorrhagic fevers. Annu Rev Pathol. 2013;8(1):411–440.
   PubMedGoogle Scholar
• Falasca L, Agrati C, Petrosillo N, et al. Molecular mechanisms of Ebola virus pathogenesis: focus on cell death. Cell Death Differ. 2015;22(8):1250–1259.
   PubMed Web of Science ®Google Scholar
• Connolly-Andersen AM, Whitaker H, Klingström J, et al. Risk of venous thromboembolism following hemorrhagic fever with renal syndrome: a self-controlled case series study. Clin Infect Dis. 2018;66(2):268–273.
   PubMed Web of Science ®Google Scholar
• Sundberg E, Hultdin J, Nilsson S, et al. Evidence of disseminated intravascular coagulation in a hemorrhagic fever with renal syndrome-scoring models and severe illness. PLoS One. 2011;6(6):e21134.
   PubMed Web of Science ®Google Scholar
• Baskerville A, Fisher-Hoch SP, Neild GH, et al. Ultrastructural pathology of experimental Ebola haemorrhagic fever virus infection. J Pathol. 1985;147(3):199–209.
   PubMed Web of Science ®Google Scholar
• Van Der Poll T, Herwald H. The coagulation system and its function in early immune defense. Thromb Haemost. 2014;112(10):640–648.
   PubMedGoogle Scholar
• Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. 2020;18(7):1559–1561.
   PubMed Web of Science ®Google Scholar
• Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636–1643.
   PubMed Web of Science ®Google Scholar
• Adamzik M, Eggmann M, Frey UH, et al. Comparison of thromboelastometry with procalcitonin, interleukin 6, and C-reactive protein as diagnostic tests for severe sepsis in critically ill adults. Crit Care. 2010;14(5):R178.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Li Z, Zhang L, et al. Clinical features and outcomes of patients with hemophagocytic lymphohistiocytosis at onset of systemic autoinflammatory disorder and compare with Epstein-Barr virus (EBV)-related hemophagocytic lymphohistiocytosis. Medicine (Baltimore). 2020;99(1):e18503.
   PubMed Web of Science ®Google Scholar
• Jiang H, Liu L, Guo T, et al. Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy. Ann Hematol. 2019;98(7):1721–1732.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
   PubMed Web of Science ®Google Scholar
• Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020;18(7):1747–1751.
   PubMed Web of Science ®Google Scholar
• Tomasoni D, Italia L, Adamo M, et al. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. Eur J Heart Fail. 2020;22(6):957–966.
   PubMedGoogle Scholar
• Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. Hypertens Res. 2020;43(7):648–654.
   PubMed Web of Science ®Google Scholar
• Iba T, Connors JM, Levy JH. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm Res. 2020;69(12):1181–1189.
   PubMed Web of Science ®Google Scholar
• Valerio L, Ferrazzi P, Sacco C, et al. Course of D-dimer and C-reactive protein levels in survivors and nonsurvivors with COVID-19 pneumonia: a retrospective analysis of 577 patients. Thromb Haemost. 2020;121(1):98–101.
   PubMedGoogle Scholar
• Hardy M, Michaux I, Lessire S, et al. Prothrombotic disturbances of hemostasis of patients with severe COVID-19: a prospective longitudinal observational study. Thromb Res. 2020;197:20–23.
   PubMed Web of Science ®Google Scholar
• Huang I, Pranata R, Ma L, et al. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620937175.
   Web of Science ®Google Scholar
• Umemura Y, Yamakawa K, Kiguchi T, et al. Hematological phenotype of COVID-19-induced coagulopathy: far from typical sepsis-induced coagulopathy. J Clin Med. 2020;9(9):2875.
   Web of Science ®Google Scholar
• Yin S, Huang M, Li D, et al. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. In: J Thromb Thrombolysis. 2020:1–4. DOI: 10.1007/s11239-020-02105-8.
   Google Scholar
• Levi M, Thachil J. Coronavirus disease 2019 coagulopathy: disseminated intravascular coagulation and thrombotic microangiopathy-either, neither, or both. Semin Thromb Hemost. 2020;46(7):781–784.
   PubMedGoogle Scholar
• Dolhnikoff M, Duarte-Neto AN, De Almeida Monteiro RA, et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost. 2020;18(6):1517–1519.
   PubMed Web of Science ®Google Scholar
• Rapkiewicz AV, Mai X, Carsons SE, et al. Megakaryocytes and platelet-fibrin thrombi characterize multiorgan thrombosis at autopsy in COVID-19: a case series. EClinicalMedicine. 2020;24:100434.
   PubMedGoogle Scholar
• Liao D, Zhou F, Luo L, et al. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol. 2020;7(9):e671–e678.
   PubMed Web of Science ®Google Scholar
• Gando S, Shiraishi A, Yamakawa K, et al. Role of disseminated intravascular coagulation in severe sepsis. Thromb Res. 2019;178:182–188.
   PubMed Web of Science ®Google Scholar
• Watchmaker JM, Goldman DT, Lee JY, et al. Increased incidence of acute pulmonary embolism in emergency department patients during the COVID-19 pandemic. Acad Emerg Med. 2020 Oct;5. DOI:10.1111/acem.14148
   Google Scholar
• COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators. Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med. 2020;47(1):60-73.
   Web of Science ®Google Scholar
• Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089–1098.
   PubMed Web of Science ®Google Scholar
• Poissy J, Goutay J, Caplan M, et al. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation. 2020;142(2):184–186.
   PubMed Web of Science ®Google Scholar
• D’Alto M, Marra AM, Severino S, et al. Right ventricular-arterial uncoupling independently predicts survival in COVID-19 ARDS. Crit Care. 2020;24(1):670.
   PubMed Web of Science ®Google Scholar
• Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120–128.
   PubMed Web of Science ®Google Scholar
• Shi L, Xu J, Duan G, et al. The pooled prevalence of pulmonary embolism in patients with COVID-19. Intensive Care Med. 2020;46(11):2089–2091.
   PubMed Web of Science ®Google Scholar
• Okada H, Yoshida S, Hara A, et al. Vascular endothelial injury exacerbates coronavirus disease 2019: the role of endothelial glycocalyx protection. In: Microcirculation. 2020. p. e12654. DOI: 10.1111/micc.12654.
   Google Scholar
• Li S, Jiang L, Li X, et al. Clinical and pathological investigation of patients with severe COVID-19. JCI Insight. 2020;5(12):e138070.
   PubMed Web of Science ®Google Scholar
• Moore HB, Moore EE, Gonzalez E, et al. Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy. J Trauma Acute Care Surg. 2014;77(6):811–817.
   PubMedGoogle Scholar
• Wright FL, Vogler TO, Moore EE, et al. Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 infection. J Am Coll Surg. 2020;231(2):193–203.e1.
   PubMed Web of Science ®Google Scholar
• Keshari RS, Silasi R, Popescu NI, et al. CD14 inhibition improves survival and attenuates thrombo-inflammation and cardiopulmonary dysfunction in a baboon model of Escherichia coli sepsis. J Thromb Haemost. 2020 Nov 10. DOI:10.1111/jth.15162.
   Web of Science ®Google Scholar
• Zuo Y, Warnock M, Harbaugh A, et al. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. Sci Rep. 2021;11(1):1580.
   Google Scholar
• Bekelis K, Missios S, Ahmad J, et al. Ischemic stroke occurs less frequently in patients with COVID-19: a multicenter cross-sectional study. Stroke. 2020;51(12):3570–3576.
   PubMed Web of Science ®Google Scholar
• Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9–14.
   PubMed Web of Science ®Google Scholar
• Connell NT, Battinelli EM, Connors JM. Coagulopathy of COVID-19 and antiphospholipid antibodies. J Thromb Haemost. 2020 May 7. DOI:10.1111/jth.14893.
   PubMed Web of Science ®Google Scholar
• Chang JC. Acute respiratory distress syndrome as an organ phenotype of vascular microthrombotic disease: based on hemostatic theory and endothelial molecular pathogenesis. Clin Appl Thromb Hemost. 2019;25:1076029619887437.
   Web of Science ®Google Scholar
• Parra-Izquierdo I, Aslan JE. Perspectives on platelet heterogeneity and host immune response in coronavirus disease 2019 (COVID-19). Semin Thromb Hemost. 2020;46(7):826–830.
   PubMedGoogle Scholar
• Zaid Y, Puhm F, Allaeys I, et al. Platelets can associate with SARS-Cov-2 RNA and are hyperactivated in COVID-19. Circ Res. 2020;127(11):1404–1418.
   Web of Science ®Google Scholar
• Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–1418.
   PubMed Web of Science ®Google Scholar
• Roncati L, Ligabue G, Fabbiani L, et al. Type 3 hypersensitivity in COVID-19 vasculitis. Clin Immunol. 2020May;29:108487.
   Google Scholar
• Llamas-Velasco M, Muñoz-Hernández P, Lázaro-González J, et al. Thrombotic occlusive vasculopathy in a skin biopsy from a livedoid lesion of a patient with COVID-19. Br J Dermatol. 2020;183(3):591–593.
   PubMed Web of Science ®Google Scholar
• Saracco P, Parodi E, Fabris C, et al. Management and investigation of neonatal thromboembolic events: genetic and acquired risk factors. Thromb Res. 2009;123(6):805–809.
   PubMed Web of Science ®Google Scholar
• Viner RM, Mytton OT, Bonell C, et al. Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. JAMA Pediatr. 2020;25:e204573.
   Google Scholar
• Bunyavanich S, Do A, Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA. 2020;323(23):2427–2429.
   PubMed Web of Science ®Google Scholar
• Weisberg SP, Connors TJ, Zhu Y, et al. Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. Nat Immunol. 2020 Nov 5. DOI:10.1038/s41590-020-00826-9.
   PubMed Web of Science ®Google Scholar
• Del Borrello G, Giraudo I, Bondone C, et al. SARS-CoV-2 associated coagulopathy and thromboembolism prophylaxis in children: a single centre observational study. J Thromb Haemost. 2020 Dec 11;19(2):522–530.
   PubMed Web of Science ®Google Scholar
• Dufort EM, Koumans EH, Chow EJ, et al. Multisystem inflammatory syndrome in children in New York state. N Engl J Med. 2020;383(4):347–358.
   PubMed Web of Science ®Google Scholar
• Pairo-Castineira E, Clohisey S, Klaric L, et al. Genetic mechanisms of critical illness in Covid-19. Nature. 2020 Dec 11;591(7848):92–98.
   PubMed Web of Science ®Google Scholar
• Del BG, Giraudo I, Bondone C, et al. SARS-COV-2-associated coagulopathy and thromboembolism prophylaxis in children: a single-center observational study. J Thromb Haemost. 2020 Dec 11. DOI:10.1111/jth.15216.
   Web of Science ®Google Scholar
• Molinari AC, Banov L, Bertamino M, et al. A practical approach to the use of low molecular weight heparins in VTE treatment and prophylaxis in children and newborns. Pediatr Hematol Oncol. 2015;32(1):1–10.
   PubMed Web of Science ®Google Scholar
• Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023–1026.
   PubMed Web of Science ®Google Scholar
• Moores LK, Tritschler T, Brosnahan S, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest. 2020;158(3):1143–1163.
   PubMed Web of Science ®Google Scholar
• Rosenman M, Liu X, Phatak H, et al. Pharmacological prophylaxis for venous thromboembolism among hospitalized patients with acute medical illness: an electronic medical records study. Am J Ther. 2016;23(2):e328–e335.
   PubMed Web of Science ®Google Scholar
• Lu YF, Pan LY, Zhang WW, et al. A meta-analysis of the incidence of venous thromboembolic events and impact of anticoagulation on mortality in patients with COVID-19. Int J Infect Dis. 2020;100:34–41.
   PubMed Web of Science ®Google Scholar
• Tremblay D, Van Gerwen M, Alsen M, et al. Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study. Blood. 2020;136(1):144–147.
   PubMed Web of Science ®Google Scholar
• Paranjpe I, Fuster V, Lala A, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020;76(1):122–124.
   PubMed Web of Science ®Google Scholar
• Lemos ACB, Da DES, Salvetti MC, et al. Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID). Thromb Res. 2020;196:359–366.
   PubMed Web of Science ®Google Scholar
• Hasan SS, Radford S, Kow CS, et al. Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis. J Thromb Thrombolysis. 2020;50(4):814–821.
   PubMed Web of Science ®Google Scholar
• Sridharan GK, Vegunta R, Rokkam VRP, et al. Venous thromboembolism in hospitalized COVID-19 patients. Am J Ther. 2020;27(6):e599–e610.
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136(4):489–500.
   PubMed Web of Science ®Google Scholar
• Marietta M, Vandelli P, Mighali P, et al. Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol. Trials. 2020;21(1):574.
   PubMed Web of Science ®Google Scholar
• Zakeri R, Bendayan R, Ashworth M, et al. A case-control and cohort study to determine the relationship between ethnic background and severe COVID-19. EClinicalMedicine. 2020;28:100574.
   PubMedGoogle Scholar
• Frydman GH, Boyer EW, Nazarian RM, et al. Coagulation status and venous thromboembolism risk in African Americans: a potential risk factor in COVID-19. Clin Appl Thromb Hemost. 2020;26:1076029620943671.
   Web of Science ®Google Scholar
• White RH, Keenan CR. Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res. 2009;123(Suppl 4):S11–17.
   PubMedGoogle Scholar
• Fogarty H, Townsend L, Ni Cheallaigh C, et al. COVID-19 coagulopathy in Caucasian patients. Br J Haematol. 2020;189(6):1044–1049.
   PubMed Web of Science ®Google Scholar
• Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–436.
   PubMed Web of Science ®Google Scholar
• Lev EI, Bliden KP, Jeong Y-H, et al. Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients. J Am Heart Assoc. 2014;3(5):e001167.
   PubMed Web of Science ®Google Scholar
• Chaudhary R, Bliden KP, Kreutz RP, et al. Race-related disparities in COVID-19 thrombotic outcomes: beyond social and economic explanations. EClinicalMedicine. 2020;29:100647.
   PubMedGoogle Scholar
• Sueta D, Kaikita K, Matsushita K, et al. eThrombosis: a new risk factor for venous thromboembolism in the pandemic era. Res Pract Thromb Haemost. 2021;5(1):243–244.
   PubMed Web of Science ®Google Scholar